Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia

Press/Media

Period14 Dec 2018

Media coverage

1

Media coverage

  • TitleSunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
    Media name/outletPlus Company Updates (PCU)
    Country/TerritoryUnited States
    Date14/12/18
    PersonsEric Nestler
View all 1
View less